The trajectory of prognostication and risk stratification for patients with myelodysplastic syndromes

2.

Malcovati

L

,

Ambaglio

I

,

Elena

C

.

The genomic landscape of myeloid neoplasms with myelodysplasia and its clinical implications

.

Curr Opin Oncol

.

2015

;

27

(

6

):

551

-

559

.

3.

Block

M

,

Jacobson

LO

,

Bethard

WF

.

Preleukemic acute human leukemia

.

J Am Med Assoc

.

1953

;

152

(

11

):

1018

-

1028

.

4.

Meacham

GC

,

Weisberger

AS

.

Early atypical manifestations of leukemia

.

Ann Intern Med

.

1954

;

41

(

4

):

780

-

797

.

5.

Fisher

WB

,

Armentrout

SA

,

Weisman

R

,

Graham

RC

.

“Preleukemia.” A myelodysplastic syndrome often terminating in acute leukemia

.

Arch Intern Med

.

1973

;

132

(

2

):

226

-

232

.

6.

Blair

TR

,

Bayrd

ED

,

Pease

GI

.

Atypical leukemia

.

JAMA

.

1966

;

198

(

1

):

139

-

142

.

7.

Saarni

MI

,

Linman

JW

.

Preleukemia. The hematologic syndrome preceding acute leukemia

.

Am J Med

.

1973

;

55

(

1

):

38

-

48

.

8.

Linman

JW

,

Bagby

GC

.

The preleukemic syndrome (hemopoietic dysplasia)

.

Cancer

.

1978

;

42

(

suppl 2

):

854

-

864

.

9.

Bennett

JM

,

Catovsky

D

,

Daniel

MT

, et al.

Proposals for the classification of the myelodysplastic syndromes

.

Br J Haematol

.

1982

;

51

(

2

):

189

-

199

.

10.

Greenberg

PL

,

Nichols

WC

,

Schrier

SL

.

Granulopoiesis in acute myeloid leukemia and preleukemia

.

N Engl J Med

.

1971

;

284

(

22

):

1225

-

1232

.

11.

Senn

JS

,

Pinkerton

PH

.

Defective in vitro colony formation by human bone marrow preceding overt leukaemia

.

Br J Haematol

.

1972

;

23

(

3

):

277

-

281

.

12.

Greenberg

PL

,

Mara

B

.

The preleukemic syndrome: correlation of in vitro parameters of granulopoiesis with clinical features

.

Am J Med

.

1979

;

66

(

6

):

951

-

958

.

13.

Sanz

GF

,

Sanz

MA

,

Vallespi

T

, et al.

Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients

.

Blood

.

1989

;

74

(

1

):

395

-

408

.

14.

Mufti

GJ

,

Stevens

JR

,

Oscier

DG

,

Hamblin

TJ

,

Machin

D

.

Myelodysplastic syndromes: a scoring system with prognostic significance

.

Br J Haematol

.

1985

;

59

(

3

):

425

-

433

.

15.

Aul

C

,

Gattermann

N

,

Heyll

A

,

Germing

U

,

Derigs

G

,

Schneider

W

.

Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system

.

Leukemia

.

1992

;

6

(

1

):

52

-

59

.

16.

Morel

P

,

Hebbar

M

,

Lai

JL

, et al.

Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases

.

Leukemia

.

1993

;

7

(

9

):

1315

-

1323

.

17.

Toyama

K

,

Ohyashiki

K

,

Yoshida

Y

, et al.

Clinical implications of chromosomal abnormalities in 401 patients with myelodysplastic syndromes: a multicentric study in Japan

.

Leukemia

.

1993

;

7

(

4

):

499

-

508

.

18.

Oscier

DG

.

Myelodysplastic syndromes

.

Baillieres Clin Haematol

.

1987

;

1

(

2

):

389

-

426

.

19.

Tricot

G

,

Boogaerts

MA

,

De Wolf-Peeters

C

,

Van den Berghe

H

,

Verwilghen

RL

.

The myelodysplastic syndromes: different evolution patterns based on sequential morphological and cytogenetic investigations

.

Br J Haematol

.

1985

;

59

(

4

):

659

-

670

.

20.

Jacobs

RH

,

Cornbleet

MA

,

Vardiman

JW

,

Larson

RA

,

Le Beau

MM

,

Rowley

JD

.

Prognostic implications of morphology and karyotype in primary myelodysplastic syndromes

.

Blood

.

1986

;

67

(

6

):

1765

-

1772

.

21.

Yunis

JJ

,

Lobell

M

,

Arnesen

MA

, et al.

Refined chromosome study helps define prognostic subgroups in most patients with primary myelodysplastic syndrome and acute myelogenous leukaemia

.

Br J Haematol

.

1988

;

68

(

2

):

189

-

194

.

22.

Pierre

RV

,

Catovsky

D

,

Mufti

GJ

, et al.

Clinical-cytogenetic correlations in myelodysplasia (preleukemia)

.

Cancer Genet Cytogenet

.

1989

;

40

(

2

):

149

-

161

.

23.

Greenberg

P

,

Cox

C

,

LeBeau

MM

, et al.

International scoring system for evaluating prognosis in myelodysplastic syndromes

.

Blood

.

1997

;

89

(

6

):

2079

-

2088

.

24.

Malcovati

L

,

Porta

MG

,

Pascutto

C

, et al.

Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making

.

J Clin Oncol

.

2005

;

23

(

30

):

7594

-

7603

.

25.

Malcovati

L

,

Germing

U

,

Kuendgen

A

, et al.

Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes

.

J Clin Oncol

.

2007

;

25

(

23

):

3503

-

3510

.

26.

Kantarjian

H

,

O'Brien

S

,

Ravandi

F

, et al.

Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System

.

Cancer

.

2008

;

113

(

6

):

1351

-

1361

.

27.

Della Porta

MG

,

Malcovati

L

,

Strupp

C

, et al.

Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome

.

Haematologica

.

2011

;

96

(

3

):

441

-

449

.

28.

Vardiman

JW

,

Thiele

J

,

Arber

DA

, et al.

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

.

Blood

.

2009

;

114

(

5

):

937

-

951

.

29.

Della Porta

MG

,

Tuechler

H

,

Malcovati

L

, et al.

Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM)

.

Leukemia

.

2015

;

29

(

7

):

1502

-

1513

.

30.

Fenaux

P

,

Rose

C

.

Impact of iron overload in myelodysplastic syndromes

.

Blood Rev

.

2009

;

23

(

suppl 1

):

S15

-

19

.

31.

Garcia-Manero

G

,

Shan

J

,

Faderl

S

, et al.

A prognostic score for patients with lower risk myelodysplastic syndrome

.

Leukemia

.

2008

;

22

(

3

):

538

-

543

.

32.

Itzykson

R

,

Thepot

S

,

Quesnel

B

, et al.

Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine

.

Blood

.

2011

;

117

(

2

):

403

-

411

.

33.

Fenaux

P

,

Mufti

GJ

,

Hellstrom-Lindberg

E

, et al.

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

.

Lancet Oncol

.

2009

;

10

(

3

):

223

-

232

.

34.

Wimazal

F

,

Sperr

WR

,

Kundi

M

, et al.

Prognostic value of lactate dehydrogenase activity in myelodysplastic syndromes

.

Leuk Res

.

2001

;

25

(

4

):

287

-

294

.

35.

Germing

U

,

Hildebrandt

B

,

Pfeilstocker

M

, et al.

Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS)

.

Leukemia

.

2005

;

19

(

12

):

2223

-

2231

.

36.

Sanz

G

,

Nomdedeu

B

,

Such

E

, et al.

Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome

.

Blood

.

2008

;

112

(

11

):

640

.

37.

Gatto

S

,

Ball

G

,

Onida

F

,

Kantarjian

HM

,

Estey

EH

,

Beran

M

.

Contribution of beta-2 microglobulin levels to the prognostic stratification of survival in patients with myelodysplastic syndrome (MDS)

.

Blood

.

2003

;

102

(

5

):

1622

-

1625

.

38.

Neumann

F

,

Gattermann

N

,

Barthelmes

HU

,

Haas

R

,

Germing

U

.

Levels of beta 2 microglobulin have a prognostic relevance for patients with myelodysplastic syndrome with regard to survival and the risk of transformation into acute myelogenous leukemia

.

Leuk Res

.

2009

;

33

(

2

):

232

-

236

.

39.

Verburgh

E

,

Achten

R

,

Maes

B

, et al.

Additional prognostic value of bone marrow histology in patients subclassified according to the International Prognostic Scoring System for myelodysplastic syndromes

.

J Clin Oncol

.

2003

;

21

(

2

):

273

-

282

.

40.

Della Porta

MG

,

Malcovati

L

,

Boveri

E

, et al.

Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes

.

J Clin Oncol

.

2009

;

27

(

5

):

754

-

762

.

41.

Buesche

G

,

Teoman

H

,

Wilczak

W

, et al.

Marrow fibrosis predicts early fatal marrow failure in patients with myelodysplastic syndromes

.

Leukemia

.

2008

;

22

(

2

):

313

-

322

.

42.

Wang

R

,

Gross

CP

,

Halene

S

,

Ma

X

.

Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes

.

Leuk Res

.

2009

;

33

(

12

):

1594

-

1598

.

43.

Naqvi

K

,

Garcia-Manero

G

,

Sardesai

S

, et al.

Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model

.

J Clin Oncol

.

2011

;

29

(

16

):

2240

-

2246

.

44.

Schanz

J

,

Tuchler

H

,

Sole

F

, et al.

New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge

.

J Clin Oncol

.

2012

;

30

(

8

):

820

-

829

.

45.

Greenberg

PL

,

Tuechler

H

,

Schanz

J

, et al.

Revised international prognostic scoring system for myelodysplastic syndromes

.

Blood

.

2012

;

120

(

12

):

2454

-

2465

.

46.

Pfeilstocker

M

,

Tuchler

H

,

Schonmetzler

A

,

Nosslinger

T

,

Pittermann

E

.

Time changes in predictive power of established and recently proposed clinical, cytogenetical and comorbidity scores for myelodysplastic syndromes

.

Leuk Res

.

2012

;

36

(

2

):

132

-

139

.

47.

Voso

MT

,

Fenu

S

,

Latagliata

R

, et al.

Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database

.

J Clin Oncol

.

2013

;

31

(

21

):

2671

-

2677

.

48.

Neukirchen

J

,

Lauseker

M

,

Blum

S

, et al.

Validation of the revised international prognostic scoring system (IPSS-R) in patients with myelodysplastic syndrome: a multicenter study

.

Leuk Res

.

2014

;

38

(

1

):

57

-

64

.

49.

de Swart

L

,

Smith

A

,

Johnston

TW

, et al.

Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry

.

Br J Haematol

.

2015

;

170

(

3

):

372

-

383

.

50.

Ok

CY

,

Hasserjian

RP

,

Fox

PS

, et al.

Application of the international prognostic scoring system-revised in therapy-related myelodysplastic syndromes and oligoblastic acute myeloid leukemia

.

Leukemia

.

2014

;

28

(

1

):

185

-

189

.

51.

Kuendgen

A

,

Nomdedeu

M

,

Tuechler

H

, et al.

Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification – an approach to classification of patients with t-MDS

.

Leukemia

.

2021

;

35

(

3

):

835

-

849

.

52.

Patel

SS

,

Sekeres

MA

,

Nazha

A

.

Prognostic models in predicting outcomes in myelodysplastic syndromes after hypomethylating agent failure

.

Leuk Lymphoma

.

2017 11

;

58

(

11

):

2532

-

2539

.

53.

Sakatoku

K

,

Takeoka

Y

,

Miura

A

, et al.

Combination of frailty status and comorbidity score improves the stratification of survival in patients with myelodysplastic syndrome owing to good predictive capability for infection-related mortality

.

Clin Lymphoma Myeloma Leuk

.

2019

;

19

(

12

):

799

-

805

.

54.

Starkman

R

,

Alibhai

S

,

Wells

RA

, et al.

An MDS-specific frailty index based on cumulative deficits adds independent prognostic information to clinical prognostic scoring

.

Leukemia

.

2020

;

34

(

5

):

1394

-

1406

.

55.

Stauder

R

,

Yu

G

,

Koinig

KA

, et al.

Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study

.

Leukemia

.

2018

;

32

(

6

):

1380

-

1392

.

56.

Stauder

R

,

Nosslinger

T

,

Pfeilstocker

M

, et al.

Impact of age and comorbidity in myelodysplastic syndromes

.

J Natl Compr Canc Netw

.

2008

;

6

(

9

):

927

-

934

.

57.

Wouters

H

,

Conrads-Frank

A

,

Koinig

KA

, et al.

The anemia-independent impact of myelodysplastic syndromes on health-related quality of life

.

Ann Hematol

.

2021

;

100

(

12

):

2921

-

2932

.

58.

Abel

GA

,

Efficace

F

,

Buckstein

RJ

, et al.

Prospective international validation of the Quality of Life in Myelodysplasia Scale (QUALMS)

.

Haematologica

.

2016

;

101

(

6

):

781

-

788

.

59.

Abel

GA

,

Hebert

D

,

Lee

C

, et al.

Health-related quality of life and vulnerability among people with myelodysplastic syndromes: a US National Study

.

Blood Adv

.

2023

;

7

(

14

):

3506

-

3515

.

60.

Bejar

R

,

Stevenson

K

,

Abdel-Wahab

O

, et al.

Clinical effect of point mutations in myelodysplastic syndromes

.

N Engl J Med

.

2011

;

364

(

26

):

2496

-

2506

.

61.

Papaemmanuil

E

,

Gerstung

M

,

Malcovati

L

, et al.

Clinical and biological implications of driver mutations in myelodysplastic syndromes [quiz]

.

Blood

.

2013

;

122

(

22

):

3616

-

3627

.

62.

Haferlach

T

,

Nagata

Y

,

Grossmann

V

, et al.

Landscape of genetic lesions in 944 patients with myelodysplastic syndromes

.

Leukemia

.

2014

;

28

(

2

):

241

-

247

.

63.

Nazha

A

,

Al-Issa

K

,

Hamilton

BK

, et al.

Adding molecular data to prognostic models can improve predictive power in treated patients with myelodysplastic syndromes

.

Leukemia

.

2017

;

31

(

12

):

2848

-

2850

.

64.

Bersanelli

M

,

Travaglino

E

,

Meggendorfer

M

, et al.

Classification and personalized prognostic assessment on the basis of clinical and genomic features in myelodysplastic syndromes

.

J Clin Oncol

.

2021

;

39

(

11

):

1223

-

1233

.

65.

Nazha

A

,

Komrokji

R

,

Meggendorfer

M

, et al.

Personalized prediction model to risk stratify patients with myelodysplastic syndromes

.

J Clin Oncol

.

2021

;

39

(

33

):

3737

-

3746

.

66.

Radakovich

N

,

Sallman

DA

,

Buckstein

R

, et al.

A machine learning model of response to hypomethylating agents in myelodysplastic syndromes

.

iScience

.

2022

;

25

(

10

):

104931

.

67.

GenoMed4All consortium

.

A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort study

.

Lancet Haematol

.

2023

;

10

(

2

):

e117

-

e128

.

68.

Bernard

E

,

Tuechler

H

,

Greenberg

PL

, et al.

Molecular international prognostic scoring system for myelodysplastic syndromes

.

NEJM Evid

.

2022

;

1

(

7

). Evidoa2200008.

69.

Baer

C

,

Huber

S

,

Hutter

S

, et al.

Risk prediction in MDS: independent validation of the IPSS-M-ready for routine?

.

Leukemia

.

2023

;

37

(

4

):

938

-

941

.

70.

Sauta

E

,

Robin

M

,

Bersanelli

M

, et al.

Real-world validation of molecular international prognostic scoring system for myelodysplastic syndromes

.

J Clin Oncol

.

2023

;

41

(

15

):

2827

-

2842

.

71.

Khoury

JD

,

Solary

E

,

Abla

O

, et al.

The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms

.

Leukemia

.

2022

;

36

(

7

):

1703

-

1719

.

72.

Arber

DA

,

Orazi

A

,

Hasserjian

RP

, et al.

International consensus classification of myeloid neoplasms and acute leukemia: integrating morphological, clinical, and genomic data

.

Blood

.

2022

;

140

(

11

):

1200

-

1228

.

73.

Zhang

Y

,

Wu

J

,

Xu

Z

, et al.

Impact of the International Consensus Classification of myelodysplastic syndromes

.

Br J Haematol

.

2023

;

201

(

3

):

443

-

448

.

74.

Paterlini

M

.

There shall be order. The legacy of Linnaeus in the age of molecular biology

.

EMBO Rep

.

2007

;

8

(

9

):

814

-

816

.

75.

Bernard

E

,

Hasserjian

R

,

Greenberg

PL

, et al.

Genomic classification of myelodysplastic syndromes

.

Leuk Res

.

2023

:

128S

.

76.

Gerstung

M

,

Pellagatti

A

,

Malcovati

L

, et al.

Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes

.

Nat Commun

.

2015

;

6

:

5901

.

77.

Shiozawa

Y

,

Malcovati

L

,

Galli

A

, et al.

Gene expression and risk of leukemic transformation in myelodysplasia

.

Blood

.

2017

;

130

(

24

):

2642

-

2653

.

78.

Im

H

,

Rao

V

,

Sridhar

K

, et al.

Distinct transcriptomic and exomic abnormalities within myelodysplastic syndrome marrow cells

.

Leuk Lymphoma

.

2018

;

59

(

12

):

2952

-

2962

.

79.

Kwok

B

,

Hall

JM

,

Witte

JS

, et al.

MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance

.

Blood

.

2015

;

126

(

21

):

2355

-

2361

.

80.

Galli

A

,

Todisco

G

,

Catamo

E

, et al.

Relationship between clone metrics and clinical outcome in clonal cytopenia

.

Blood

.

2021

;

138

(

11

):

965

-

976

.

81.

Malcovati

L

,

Galli

A

,

Travaglino

E

, et al.

Clinical significance of somatic mutation in unexplained blood cytopenia

.

Blood

.

2017

;

129

(

25

):

3371

-

3378

.

82.

Weeks

LD

,

Niroula

A

,

Neuberg

D

, et al.

Prediction of risk for myeloid malignancy in clonal hematopoiesis

.

NEJM Evid

.

2023

;

2

(

5

).